EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease



Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease



Journal of Rheumatology. Supplement 48: 72-78



Some types of severe autoimmune disease are associated with significant morbidity and a high mortality rate. Many of these cases occur in young adults who, even if they survive, become severely debilitated. Systemic sclerosis (SSc) is a paradigm for other severe autoimmune diseases in which patients with poor prognostic features can be identified early in the course of the disease. Allogeneic marrow transplantation may be effective for the control of autoimmune diseases like SSc because the preparative regimen will significantly suppress the host immune system and the antihost effects of the donor immune system in the engrafted marrow will help maintain the suppression of the host immune system. Considering the morbidity and poor prognosis associated with severe SSc and the favorable outcome now associated with allogeneic marrow transplantation from HLA identical siblings for other nonmalignant diseases, Phase I and II studies are warranted. These will evaluate the safety of allogeneic marrow transplantation and explore its role in the management and control of a severe autoimmune disease. We review issues important in the development of an allogeneic morrow transplant protocol for severe SSc, including patient selection, plan of treatment, prevention of graft versus host disease, supportive care, and evaluation after transplant.

(PDF emailed within 1 workday: $29.90)

Accession: 008452423

Download citation: RISBibTeXText

PMID: 9150123



Related references

Treatment of Severe Systemic Sclerosis with Allogeneic Marrow Transplantation. Blood 100(11): Abstract No 5418, November 16, 2002

Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis and Rheumatism 54(6): 1982-1986, 2006

Chronic graft versus host disease, as a systemic autoimmune disease, following allogeneic bone marrow transplantation. Periodicum Biologorum 98(4): 459-461, 1996

Nonmyeloablative allogeneic bone marrow transplantation of a child with systemic autoimmune disease and lung vasculitis. Immunologic Research 41(1): 26-33, 2008

Treatment of systemic and organ-specific autoimmune disease in mice by allogeneic bone marrow transplantation. Progress in Clinical and Biological Research 229: 131-146, 1987

Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis. Revista Brasileira de Hematologia E Hemoterapia 35(2): 134-143, 2013

A case of severe autoimmune haemolytic anemia and autoimmune thrombocytopenia in a patient 9 years after allogeneic bone marrow transplantation for severe aplastic anemia. Onkologie 18(SUPPL 2): 158, 1995

Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation. Blood 105(7): 2991-2994, 2004

Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation. Blood 105(7): 2991-2994, 2005

Severe autoimmune thrombocytopenia after allogeneic bone marrow transplantation for aplastic anemia. International Journal of Hematology 74(2): 228-232, August, 2001

Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proceedings of the National Academy of Sciences of the United States of America 86(9): 3306-3310, 1989

Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases?. Stem Cells 12(1): 125-135, 1994

Reversal of severe bone marrow fibrosis and osteo sclerosis following allogeneic bone marrow transplantation for chronic granulocytic leukemia. British Journal of Haematology 52(2): 189-194, 1982

Expression of CD27 on peripheral CD4+ T-lymphocytes correlates with the development of severe acute graft-versus-host disease after allogeneic bone marrow transplantation. International Journal of Hematology 84(4): 367-376, 2006

Allogeneic bone marrow transplantation for autoimmune disease--the jury is still out. Journal of Rheumatology 33(4): 644-646, 2006